Literature DB >> 31745979

The genomic landscape of nonsmall cell lung carcinoma in never smokers.

Bram Boeckx1,2, Rajendra B Shahi3, Dominiek Smeets1,2, Sylvia De Brakeleer3, Lore Decoster3, Thomas Van Brussel1,2, Daniella Galdermans4, Piet Vercauter5, Lynn Decoster6, Patrick Alexander7, Guy Berchem8, Sebahat Ocak9,10, Peter Vuylsteke11, Koen Deschepper12, Marc Lambrechts13, Nadia Cappoen3, Erik Teugels3, Diether Lambrechts1,2, Jacques De Greve3.   

Abstract

Lung cancer is the number one cause of cancer-related death worldwide with cigarette smoking as its major risk factor. Although the incidence of lung cancer in never smokers is rising, this subgroup of patients is underrepresented in genomic studies of lung cancer. Here, we assembled a prospective cohort of 46 never-smoking, nonsmall cell lung cancer (NSCLC) patients and performed whole-exome and low-coverage whole-genome sequencing on tumors and matched germline DNA. We observed fewer somatic mutations, genomic breakpoints and a smaller fraction of the genome with chromosomal instability in lung tumors from never smokers compared to smokers. The lower number of mutations, enabled us to identify TSC22D1 as a potential driver gene in NSCLC. On the other hand, the frequency of mutations in actionable genes such as EGFR and ERBB2 and of amplifications in MET were higher, while the mutation rate of TP53, which is a negative prognostic factor, was lower in never smokers compared to smokers. Together, these observations suggest a more favorable prognosis for never smokers with NSCLC. Classification of somatic mutations into six-substitution type patterns or into 96-substitution type signatures revealed distinct clusters between smokers and never smokers. Particularly, we identified in never smokers signatures related to aging, homologous recombination damage and APOBEC/AID activity as the most important underlying processes of NSCLC. This further indicates that second-hand smoking is not driving NSCLC pathogenesis in never smokers.
© 2019 UICC.

Entities:  

Keywords:  lung cancer; never smokers; whole-exome sequencing

Mesh:

Substances:

Year:  2019        PMID: 31745979     DOI: 10.1002/ijc.32797

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.

Authors:  Ayse Bassez; Hanne Vos; Laurien Van Dyck; Giuseppe Floris; Ingrid Arijs; Christine Desmedt; Bram Boeckx; Marlies Vanden Bempt; Ines Nevelsteen; Kathleen Lambein; Kevin Punie; Patrick Neven; Abhishek D Garg; Hans Wildiers; Junbin Qian; Ann Smeets; Diether Lambrechts
Journal:  Nat Med       Date:  2021-05-06       Impact factor: 53.440

2.  Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?

Authors:  Jacques De Greve; Philippe Giron
Journal:  Transl Lung Cancer Res       Date:  2020-02

3.  A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling.

Authors:  Junbin Qian; Siel Olbrecht; Bram Boeckx; Hanne Vos; Damya Laoui; Emre Etlioglu; Els Wauters; Valentina Pomella; Sara Verbandt; Pieter Busschaert; Ayse Bassez; Amelie Franken; Marlies Vanden Bempt; Jieyi Xiong; Birgit Weynand; Yannick van Herck; Asier Antoranz; Francesca Maria Bosisio; Bernard Thienpont; Giuseppe Floris; Ignace Vergote; Ann Smeets; Sabine Tejpar; Diether Lambrechts
Journal:  Cell Res       Date:  2020-06-19       Impact factor: 25.617

Review 4.  Lung cancer in never smokers: Tumor immunology and challenges for immunotherapy.

Authors:  Viviane Teixeira L de Alencar; Amanda B Figueiredo; Marcelo Corassa; Kenneth J Gollob; Vladmir C Cordeiro de Lima
Journal:  Front Immunol       Date:  2022-08-24       Impact factor: 8.786

5.  Tracing the evolution of aneuploid cancers by multiregional sequencing with CRUST.

Authors:  Subhayan Chattopadhyay; Jenny Karlsson; Anders Valind; Natalie Andersson; David Gisselsson
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

6.  Genetic and microenvironmental differences in non-smoking lung adenocarcinoma patients compared with smoking patients.

Authors:  Qihai Sui; Jiaqi Liang; Zhengyang Hu; Zhencong Chen; Guoshu Bi; Yiwei Huang; Ming Li; Cheng Zhan; Zongwu Lin; Qun Wang
Journal:  Transl Lung Cancer Res       Date:  2020-08

7.  High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary Adenocarcinoma.

Authors:  Arik Bernard Schulze; Anna Kuntze; Lars Henning Schmidt; Michael Mohr; Alessandro Marra; Ludger Hillejan; Christian Schulz; Dennis Görlich; Wolfgang Hartmann; Annalen Bleckmann; Georg Evers
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639

8.  Using Population-Based Cancer Registration Data and Period Analysis to Accurately Assess and Predict 5-Year Relative Survival for Lung Cancer Patients in Eastern China.

Authors:  Runhua Li; Min Zhang; Yongran Cheng; Xiyi Jiang; Huijuan Tang; Liangyou Wang; Tianhui Chen; Bicheng Chen
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.